Atossa Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Atossa Therapeutics est Steve Quay, nommé en Apr2009, a un mandat de 15.58 ans. La rémunération annuelle totale est $ 2.36M, composée du salaire de 30% et des bonus 70%, y compris les actions et options de la société. détient directement 0.002% des actions de la société, d'une valeur de € 3.09K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 12.8 ans.

Informations clés

Steve Quay

Directeur général

US$2.4m

Rémunération totale

Pourcentage du salaire du PDG	30.0%
Durée du mandat du directeur général	15.6yrs
Propriété du PDG	0.002%
Durée moyenne d'occupation des postes de direction	3.8yrs
Durée moyenne du mandat des membres du conseil d'administration	12.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Steve Quay a-t-elle évolué par rapport aux bénéfices de Atossa Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$2m	US$706k	-US$30m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$3m	US$706k	-US$27m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$6m	US$659k	-US$21m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$3m	US$601k	-US$22m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$6m	US$601k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$25m
Dec 31 2018	US$2m	US$582k	-US$23m
Sep 30 2018	n/a	n/a	-US$23m
Jun 30 2018	n/a	n/a	-US$22m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$1m	US$520k	-US$11m

Rémunération vs marché: La rémunération totale de Steve ($USD 2.36M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 786.80K ).

Rémunération et revenus: La rémunération de Steve a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Steve Quay (73 yo)

15.6yrs

Titularisation

US$2,356,220

Compensation

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Steven Quay	Chairman	15.6yrs	US$2.36m	0.0021% € 3.1k
Heather Rees	Chief Financial Officer & Principal Accounting Officer	3.8yrs	US$687.46k	0% € 0
Delly Behen	Senior Vice President of Administration & HR	10.3yrs	pas de données	pas de données
Eric Van Zanten	Vice President of Investor & Public Relations	2.8yrs	pas de données	pas de données
Richard Graydon	Interim Chief Medical Officer	2.1yrs	pas de données	pas de données

3.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de YAG2 est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Steven Quay	Chairman	15.6yrs	US$2.36m	0.0021% € 3.1k
Richard Steinhart	Independent Director	10.7yrs	US$146.17k	0% € 0
H. Remmel	Independent Director	12.8yrs	US$144.92k	0.00020% € 292.5
Shu-Chih Chen	Director	15.6yrs	US$116.17k	0.018% € 25.9k
Stephen Galli	Independent Director	13.3yrs	US$144.92k	0.000080% € 117.0
Jonathan Finn	Independent Director	less than a year	US$93.98k	0.020% € 29.1k
Tessa Cigler	Independent Director	less than a year	pas de données	pas de données

12.8yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la YAG2 est chevronné et expérimenté ( 12.8 années d'ancienneté moyenne).

Atossa Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Recent updates

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

No longer forecast to breakeven

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Forecast to breakeven in 2024

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

Atossa Therapeutics Receives Approval from Swedish Ethics Review Authority to Initiate A Phase 2 Clinical Study of Oral Endoxifen

Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery At A Webinar At 8 Am Pacific Time on June 9, 2021

Atossa Therapeutics, Inc. Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Atossa Therapeutics, Inc.'s Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to Be Halted Early

New 90-day high: €1.63

Atossa Therapeutics, Inc. has completed a Composite Units Offering in the amount of $20 million.

New 90-day low: €0.74

New 90-day low: €1.06

Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of At-301 Nasal Spray Being Developed for Covid-19

New 90-day low: €1.61

Atossa Therapeutics, Inc. Completes Enrollment of Phase 1 Clinical Study of At-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

New 90-day low - €2.17